Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: Results of a phase II study

Haematologica

Volumn 91, Issue 4, 2006, Pages 546-549

  Engert, Andreas ^a,g   Bredenfeld, Henning ^a   Döhner, Hartmut ^b   Ho, Anthony D ^c   Schmitz, Norbert ^d   Berger, Dietmar ^e   Bacon, Pamela ^e   Skacel, Tomas ^e   Easton, Valerie ^f   Diehl, Volker ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d DEPARTMENT OF CARDIOLOGY   (Germany)

^e AMGEN INC   (United States)

^f AMGEN LTD   (United Kingdom)

^g UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemotherapy; Hodgkin's lymphoma; Phase I

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ANEMIA; ARTICLE; BACKACHE; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; MALE; MUSCULOSKELETAL PAIN; NEUTROPENIA; PELVIS PAIN SYNDROME; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FILGRASTIM; HODGKIN DISEASE; HUMANS; MIDDLE AGED; PREDNISONE; PROCARBAZINE; RISK; TREATMENT OUTCOME; VINCRISTINE;

EID: 33645984557     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Sieber M, Ruffer U, Josting A, Diehl V, Jostin A. Treatment of Hodgkin's disease: current strategies of the German Hodgkin's Lymphoma Study Group. Ann Oncol 1999;10 Suppl 6:23-9.
2. Borchmann P, Schnell R, Diehl V, Engert A. New drugs in the treatment of Hodgkin's disease. Ann Oncol 1998;9 Suppl 5:S103-8.
3. Engert A, Wolf J, Diehl V. Treatment of advanced Hodgkin's lymphoma: standard and experimental approaches. Semin Hematol 1999;36:282-9
4. Tesch H, Sieber M, Diehl V. Treatment of advanced stage Hodgkin's disease. Oncology 2001;60:101-9.
5. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, Lopez-Brea M, Rueda A, Guillem V, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Nad Cancer Inst 2001;93:31-8.
6. Clark OA, Lyman G, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev 2003;CD003039.
7. Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, et al. Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993; 29A:319-24.
8. Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70.
9. Biganzoli L, Untch M, Skacel T, Pico JL. Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 2004;31 Suppl 8:27-34.
10. Vose JM, Crump M, Lazarus H, Emmanouilides C, Schenkein D, Moore J, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-9.
11. Bedell C. Pegfilgrastim for chemotherapy-induced neutropenia. Clin J Oncol Nurs 2003;7:55-6.
12. Diehl V. Dose-escalation study for the treatment of Hodgkin's disease. The German Hodgkin Study Group (GHSG). Ann Hematol 1993;66:139-40.
13. Loeffler M, Hasenclever D, Diehl V. Model based development of the BEACOPP regimen for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1998;9 Suppl 5:S73-8.
14. Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V. Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's disease. German Hodgkin's Lymphoma Study Group (GHSG). Ann Oncol 2000;11:1105-14.
15. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, et al. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:1734-9.
16. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-95.
17. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 2003;10:715-24.
18. George S, Yunus F, Case D, Yang BB, Hackett J, Shogan JE, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003;44:1691-6.